CS Medica Future Growth

Future criteria checks 2/6

CS Medica is forecast to grow earnings and revenue by 48.6% and 46.9% per annum respectively while EPS is expected to grow by 55.4% per annum.

Key information

48.6%

Earnings growth rate

55.4%

EPS growth rate

Pharmaceuticals earnings growth21.2%
Revenue growth rate46.9%
Future return on equityn/a
Analyst coverage

Low

Last updated04 Nov 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:8G8 - Analysts future estimates and past financials data (DKK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/202775N/AN/AN/A1
9/30/202654-3-301
9/30/202534-9-10-71
9/30/202416-15-20-171
6/30/20245-12-40N/A
3/31/20245-13-5-1N/A
12/31/20233-14-8-5N/A
9/30/20231-15-11-8N/A
6/30/202310-11-12-9N/A
3/31/202311-11-16-15N/A
12/31/202211-12-17-15N/A
9/30/202211-11-17-14N/A
6/30/20224-10-20-17N/A
3/31/20223-5-17-11N/A
12/31/20213-2-12-8N/A
9/30/202131-10-6N/A
6/30/202110-41N/A
9/30/202020-11N/A
9/30/20191001N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 8G8 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 8G8 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 8G8 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 8G8's revenue (46.9% per year) is forecast to grow faster than the German market (5.6% per year).

High Growth Revenue: 8G8's revenue (46.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 8G8's Return on Equity is forecast to be high in 3 years time


Discover growth companies